These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

619 related items for PubMed ID: 18388514

  • 41. Safety of anti-tumor necrosis factor agents in psoriatic arthritis - an update.
    Palazzi C, D'Angelo S, Leccese P, Padula A, Olivieri I.
    Expert Opin Drug Saf; 2014 Feb; 13(2):191-6. PubMed ID: 24219428
    [Abstract] [Full Text] [Related]

  • 42. Patient preferences for biologic agents in rheumatoid arthritis: a discrete-choice experiment.
    Augustovski F, Beratarrechea A, Irazola V, Rubinstein F, Tesolin P, Gonzalez J, Lencina V, Scolnik M, Waimann C, Navarta D, Citera G, Soriano ER.
    Value Health; 2013 Feb; 16(2):385-93. PubMed ID: 23538191
    [Abstract] [Full Text] [Related]

  • 43. Advances in the management of rheumatoid arthritis.
    Dale J.
    Scott Med J; 2015 Aug; 60(3):108-14. PubMed ID: 26122283
    [Abstract] [Full Text] [Related]

  • 44. Role of Methotrexate in the Management of Psoriatic Arthritis.
    Elmamoun M, Chandran V.
    Drugs; 2018 Apr; 78(6):611-619. PubMed ID: 29616495
    [Abstract] [Full Text] [Related]

  • 45. Initial management of rheumatoid arthritis.
    Gramling A, O'Dell JR.
    Rheum Dis Clin North Am; 2012 May; 38(2):311-25. PubMed ID: 22819086
    [Abstract] [Full Text] [Related]

  • 46. Psoriatic Disease: Update on Traditional Disease-modifying Antirheumatic Drugs.
    Marchesoni A, Lubrano E, Cauli A, Ricci M, Manara M.
    J Rheumatol Suppl; 2015 Nov; 93():61-4. PubMed ID: 26523060
    [Abstract] [Full Text] [Related]

  • 47. Disease-modifying antirheumatic drugs.
    Li E, Brooks P, Conaghan PG.
    Curr Opin Rheumatol; 1998 May; 10(3):159-68. PubMed ID: 9608316
    [Abstract] [Full Text] [Related]

  • 48. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis.
    Ravindran V, Scott DL, Choy EH.
    Ann Rheum Dis; 2008 Jun; 67(6):855-9. PubMed ID: 17827183
    [Abstract] [Full Text] [Related]

  • 49. Combination therapy with disease modifying anti-rheumatic drugs in rheumatoid arthritis.
    Garrood T, Scott DL.
    BioDrugs; 2001 Jun; 15(8):543-61. PubMed ID: 11543695
    [Abstract] [Full Text] [Related]

  • 50. Safe use of antirheumatic agents in patients with comorbidities.
    Makol A, Wright K, Matteson EL.
    Rheum Dis Clin North Am; 2012 Nov; 38(4):771-93. PubMed ID: 23137582
    [Abstract] [Full Text] [Related]

  • 51. Risk factors for cardiovascular disease in rheumatoid arthritis.
    Gabriel SE, Crowson CS.
    Curr Opin Rheumatol; 2012 Mar; 24(2):171-6. PubMed ID: 22249350
    [Abstract] [Full Text] [Related]

  • 52. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study.
    Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F.
    Lancet; 2002 Apr 06; 359(9313):1173-7. PubMed ID: 11955534
    [Abstract] [Full Text] [Related]

  • 53. Is there still a role for traditional disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis?
    Cannella AC, O'Dell JR.
    Curr Opin Rheumatol; 2003 May 06; 15(3):185-92. PubMed ID: 12707569
    [Abstract] [Full Text] [Related]

  • 54. [Leflunomide--a new disease modifying anti-rheumatic agent].
    Rødevand E, Kvien TK, Johnsen V.
    Tidsskr Nor Laegeforen; 2001 Nov 10; 121(27):3181-4. PubMed ID: 11876141
    [Abstract] [Full Text] [Related]

  • 55. Disease-modifying antirheumatic drugs: gold, penicillamine, antimalarials, and sulfasalazine.
    McConkey B.
    Curr Opin Rheumatol; 1991 Jun 10; 3(3):348-54. PubMed ID: 1679342
    [Abstract] [Full Text] [Related]

  • 56. Current immunotherapy in rheumatoid arthritis.
    Meier FM, Frerix M, Hermann W, Müller-Ladner U.
    Immunotherapy; 2013 Sep 10; 5(9):955-74. PubMed ID: 23998731
    [Abstract] [Full Text] [Related]

  • 57. Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis.
    Fleischmann R.
    Expert Opin Drug Saf; 2003 Jul 10; 2(4):347-65. PubMed ID: 12904092
    [Abstract] [Full Text] [Related]

  • 58. How to use biologic agents in patients with rheumatoid arthritis who have comorbid disease.
    Richards JS, Dowell SM, Quinones ME, Kerr GS.
    BMJ; 2015 Aug 17; 351():h3658. PubMed ID: 26282936
    [Abstract] [Full Text] [Related]

  • 59. A clinical and economic review of disease-modifying antirheumatic drugs.
    Gabriel SE, Coyle D, Moreland LW.
    Pharmacoeconomics; 2001 Aug 17; 19(7):715-28. PubMed ID: 11548909
    [Abstract] [Full Text] [Related]

  • 60. [Glucocorticoids].
    Tanaka H, Hosono O, Kobayashi H, Yoshikawa N, Matsumiya R.
    Nihon Rinsho; 2013 Jul 17; 71(7):1261-5. PubMed ID: 23961677
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.